Drug Profile
Research programme: protein targeting therapeutics - Primary Peptides
Alternative Names: PP-005Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Primary Peptides
- Class Neuroprotectants; Peptides
- Mechanism of Action Cell death modulators; JNK mitogen-activated protein kinase modulators; TDP-43 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
- Discontinued Neurodegenerative disorders; Neurological disorders
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Neurodegenerative disorders in Canada (unspecified route)
- 29 Aug 2023 Discontinued - Preclinical for Neurological disorders in Canada (unspecified route)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Huntington's-disease in Canada